Advanced Imaging in Oncology

MessageThis Webinar is over
Date Aug 24, 2016
Time 11:00 am EDT
Cost Free
Online
A wide and growing range of imaging modalities and analysis methods are available for use in oncology and hematology clinical trials. This reflects the understanding that standard assessment of change in tumor size using CT may in some cases provide an incomplete picture of disease progression or response to therapy. Furthermore, the therapeutic options for patients with cancer now include increasingly complex combinations of medications, radiation therapy, and surgical intervention. Many of these treatments have important potential adverse cardiac effects and are likely to have significant effects on patient outcomes. As such, echocardiography is being used more and more extensively as a safety biomarker to assess potential cardiac toxicity from pharmacological agents.
Join BioTelemetry Research’s Edward Ashton, PhD, Vice President, Oncology Imaging and Polina Voloshko, MD, Chief Medical Officer for a complimentary webinar on Advanced Imaging in Oncology. This webinar will address the general categories of advanced imaging applications, including:
  • Functional imaging techniques, which provide insight into both treatment mechanism of action and patient response to therapy. Examples include dynamic contrast-enhanced MRI for assessment of changes in blood flow and vascular permeability in the context of anti-vascular therapy; molecular imaging techniques such as FLT-PET for assessment of changes in tumor function, which may occur prior to changes in tumor size; and diffusion-weighted MRI for assessment of the tumor bed microenvironment.

  • Multimodality imaging, which allows a more precise assessment of a patient’s disease state compared to standard CT imaging alone. Examples include FDG-PET, used in combination with CT in the assessment of response to therapy in lymphoma and bone scintigraphy, used in combination with CT in the assessment of response to therapy in prostate cancer.

  • Echocardiography, which is used as a non-invasive method to monitor cardiotoxicity of cancer therapy. Echocardiography is a powerful imaging technique used to identify cardiac complications associated with cancer therapy. These include left ventricular (systolic and diastolic) dysfunction, valve heart disease, pericarditis, and pericardial effusion.

  • Specialized response criteria, which make use of modifications to standard RECIST assessments to account for the peculiarities of a given indication or therapy. Examples include irRC and irRECIST for assessment of response to immunotherapy, mRECIST for assessment of response in hepatocellular cancer, and RANO criteria for assessment of response in glioma.
Join this webinar as the speakers discuss the growing range of imaging modalities and analysis methods that are available for use in your clinical trials during oncology drug development.

 


comments powered by Disqus
Create your own event
Turn your passion into a business.
Join our mailing list